Publications by authors named "L Geriniere"
Article Synopsis
- Older COVID-19 patients, particularly those over 60 with comorbidities and frailty, face higher risks of mortality; thus, care limitations may be necessary for those with severe pneumonia and poor prognosis.
- This study evaluated the outcomes of these patients treated with high flow nasal oxygen (HFNO) outside of ICU settings, aiming to assess survival rates and identify factors influencing HFNO success or failure.
- Results indicated that 73% of the 56 patients studied died within 30 days; HFNO failed in 66% of cases, with certain clinical signs before treatment linked to higher mortality rates.
Background: Few data are available on programmed cell-death-protein-1-ligand-1 (PD-L1) expression on large-cell neuroendocrine carcinomas of the lung (LCNECs). We analyzed PD-L1 expression on tumor (TCs) and inflammatory cells (ICs) from LCNEC patients to assess relationships between this expression, clinical characteristics, and disease outcomes.
Methods: PD-L1 expression was determined by immunohistochemistry with monoclonal antibody 22C3 in consecutive LCNEC patients managed in 17 French centers between January 2014 and December 2016.
Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. However, data on efficacy of osimertinib in real world remain rare. Materials and methods This retrospective multicentric study analyzed T790M-positive advanced NSCLC patients enrolled in French early access program for osimertinib.
View Article and Find Full Text PDF